CryoLife Acquires Ascyrus Medical | 合法醫療器材資訊網

2020年9月2日—AccordingtoCryoLife,theAMDSisusedasacomplementto,andinconjunctionwith,hemiarchreplacementwithoutaddingtechnical ...

September 2, 2020—CryoLife, Inc. announced that it has acquired Ascyrus Medical LLC, a privately held developer of the Ascyrus Medical dissection stent (AMDS), an aortic arch remodeling device used for the treatment of acute type A aortic dissections.

CryoLife will acquire Ascyrus Medical for up to $200 million, consisting of upfront payment in $60 million cash and $20 million in CryoLife common stock; and up to $120 million in milestone payments upon various regulatory approvals in the United States, Japan, and China.

According to CryoLife, the AMDS is used as a complement to, and in conjunction with, hemiarch replacement without adding technical complexity. The design of the AMDS allows for rapid deployment of the graft in the aortic arch during a standard replacement of the ascending aorta, adding < 5 minutes to the procedure time. Deployment of the AMDS preserves the native arch,...